Image Credit: Shutterstock
Mumbai-based Bharat Serums and Vaccines has partnered with the National Chemical Laboratory (NCL), Pune, a constituent laboratory of the Council of Scientific and Industrial Research (CSIR), Government of India.
This collaboration primarily focuses on the evaluation of certain recombinant cell line technologies developed by NCL for biopharmaceutical products currently under development at BSV.
The technology involves using CRISPR/Cas9 techniques to perform specific modifications of mammalian cell lines to achieve certain desired product quality attributes.
Sanjiv Navangul, MD and CEO, BSV said, “Through this collaboration, we are delighted to tap some of the best research minds in the country to help us bring innovative treatments and cures for patients in India and the world.”